DNER and medulloblastoma: YB-1 knockdown cell lines were exposed to standard-of-care chemotherapies vincristine and cisplatin, as well as two novel anti-cancer therapies which have shown promise in medulloblastoma pre-clinical studies, JQ1 (a BET bromodomain inhibitor) and panobinostat (a histone deacetylase inhibitor).